Giorgio Orofino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giorgio Orofino has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Annalisa Ruggeri
IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Haematology and Bone Marrow Transplantation, Milano, Italy
3 shared publications Daniele Mannina
3 shared publicationsFlorent Malard
3 shared publicationsStefania Bramanti
I.R.C.C.S. Humanitas Research Hospital, Rozzano, Milan, Italy
3 shared publicationsAna Alarcon Tomas
Hospital Universitario Puerta de Hierro, Madrid, Spain
2 shared publicationsAndrea Palasciano
University College London Hospital, London, UK
2 shared publications
Latest Publications
- 25 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (23) , 2221-2232
Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation
PURPOSE: For patients with hematologic malignancies, relapse is the leading cause of death after allogeneic hematopoietic cell transplantation (allo-HCT). Frequently, relapses are explained by immune evasion through alterations of human leukocyte antigens (HLAs), but determinants and clinical consequences remain poorly defined. METHODS: We analyzed 533 relapses of hematologic cancers after allo-HCT from different donor types, conducted at 27 centers worldwide. Genomic loss of mismatched HLA (HLA loss) was assessed using a newly developed next-generation sequencing pipeline. Clinical and immunogenetic factors associated with HLA loss were evaluated. Using HLA data from approximately 5 million individuals, a web-based tool to infer HLA incompatibility phasing was developed. RESULTS: HLA loss occurred in 15.6% of relapses, with significant variation according to donor type (28.7% haploidentical family, 7.2% unrelated adult, 2.7% cord blood, P < .0001). The distribution of HLA mismatches across the patient's haplotypes, predicted through the phasing tool, was strongly associated with HLA loss, with an incidence of 27.6% when HLA mismatches were in the same haplotype, compared with 5.4% if present on different haplotypes ( P < .0001). HLA loss affected postrelapse outcomes, abrogating the efficacy of original donor lymphocyte infusions, with significant survival advantage by second allo-HCT from a different donor. CONCLUSION: The likelihood of HLA loss varies significantly according to the number and positioning of HLA mismatches between patient and donor. A newly developed phasing tool enables reliable prediction of its risk, supporting informed donor selection. Routine assessment of HLA loss at relapse is warranted, as it critically affects the success of immunologic salvage therapies.
- 25 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (23) , 2221-2232
Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation
PURPOSE: For patients with hematologic malignancies, relapse is the leading cause of death after allogeneic hematopoietic cell transplantation (allo-HCT). Frequently, relapses are explained by immune evasion through alterations of human leukocyte antigens (HLAs), but determinants and clinical consequences remain poorly defined. METHODS: We analyzed 533 relapses of hematologic cancers after allo-HCT from different donor types, conducted at 27 centers worldwide. Genomic loss of mismatched HLA (HLA loss) was assessed using a newly developed next-generation sequencing pipeline. Clinical and immunogenetic factors associated with HLA loss were evaluated. Using HLA data from approximately 5 million individuals, a web-based tool to infer HLA incompatibility phasing was developed. RESULTS: HLA loss occurred in 15.6% of relapses, with significant variation according to donor type (28.7% haploidentical family, 7.2% unrelated adult, 2.7% cord blood, P < .0001). The distribution of HLA mismatches across the patient's haplotypes, predicted through the phasing tool, was strongly associated with HLA loss, with an incidence of 27.6% when HLA mismatches were in the same haplotype, compared with 5.4% if present on different haplotypes ( P < .0001). HLA loss affected postrelapse outcomes, abrogating the efficacy of original donor lymphocyte infusions, with significant survival advantage by second allo-HCT from a different donor. CONCLUSION: The likelihood of HLA loss varies significantly according to the number and positioning of HLA mismatches between patient and donor. A newly developed phasing tool enables reliable prediction of its risk, supporting informed donor selection. Routine assessment of HLA loss at relapse is warranted, as it critically affects the success of immunologic salvage therapies.
- Open Access
- 11 June 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 96, 104014
Fertility management and outcomes after CAR T-cell therapy: an international survey from the Cellular Therapy and Immunobiology working party of the European Society for Blood and Marrow Transplantation
- 11 June 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 96, 104014
Open AccessFertility management and outcomes after CAR T-cell therapy: an international survey from the Cellular Therapy and Immunobiology working party of the European Society for Blood and Marrow Transplantation
- Open Access
- 11 February 2026
- Published by Elsevier in SSRN Electronic Journal
Fertility after CAR T-Cell Therapy, a Survey on Management and Outcomes from the Cellular Therapy and Immunobiology Working Party of the EBMT
Introduction: CAR T-cell therapy has become a highly effective treatment for hematological malignancies, and emerging evidence indicates promising benefits for non oncohematological conditions. As its clinical use broadens, understanding long-term outcomes and late complications is increasingly crucial. One critical yet understudied area is fertility, for which current evidence remains limited and no formal guidelines provide direction for patients undergoing CAR T-cell therapy. Methods: To address this gap, we conducted a cross-sectional survey on behalf of the Cellular Therapy and Immunobiology Working Party (CTIWP) of the EBMT, distributed from January to April 2025 to centers, assessing current fertility-related practices around CAR T-cell therapy. A second, complementary questionnaire was then circulated to gather detailed information on reported pregnancies following CAR T treatment. Results: In total, 99 centers out of 247 (40%) answered and were included in the analysis. A total of 23 pregnancies were reported in 18 patients, resulting in 18 live births, 1 ongoing pregnancy, and 4 miscarriages at the time of data censoring. Seventeen pregnancies occurred in female CAR T-cell recipients, and six were reported by male recipients through their partners. In patient achieving pregnancy, B cell lymphoma was the most common indication for treatment. Notably, pregnancies in the female cohort occurred naturally in 82% of cases (14/17). Among the patients with available information, the median time between CAR T-cell infusion and delivery or miscarriage was 3 years, (range 4 months to 6 years). Although both low- and high-grade Cytokine Release Syndrome (CRS) and Immune Effector Cell–Associated Neurotoxicity Syndrome (ICANS) were reported among these patients, these events did not appear to influence pregnancy outcomes, acknowledging the small sample size. Moreover, with the questionnaire we assessed the different procedures regarding fertility across centers. While most centers reported offering fertility counselling before CAR T-cell infusion, 11 centers (17%) indicated that they do not routinely inform patients of the potential reproductive risks; indeed, most centers (79%) offered fertility preservation procedures to male and female patients. Additionally, 41 % of the reporting centers do not routinely provide psychological support during CAR T-cell therapy. The most common barriers to fertility preservation referral were the urgency of initiating bridging therapy to CAR T-cell infusions due to active or rapidly progressive disease in aggressive disease and extensive prior chemotherapy exposure, defined as more than three previous treatment lines. Among male patients, semen collection and cryopreservation were the most frequently used methods (93%). For female patients, the predominant approaches were oocyte cryopreservation (63%) and ovarian tissue cryopreservation (59%). Endocrinologic follow-up practices after CAR T-cell therapy varied substantially across centers. Conclusions: We report the largest series of pregnancies and live births after–CAR T. As CAR T-cell therapy is increasingly administered earlier in the treatment algorithms and to younger populations, integrating standardized fertility counselling and preservation strategies into routine care will be essential. The reproductive success highlights the urgent need for robust research and formalized guidelines in this evolving field.
- 11 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessFertility after CAR T-Cell Therapy, a Survey on Management and Outcomes from the Cellular Therapy and Immunobiology Working Party of the EBMT
Introduction: CAR T-cell therapy has become a highly effective treatment for hematological malignancies, and emerging evidence indicates promising benefits for non oncohematological conditions. As its clinical use broadens, understanding long-term outcomes and late complications is increasingly crucial. One critical yet understudied area is fertility, for which current evidence remains limited and no formal guidelines provide direction for patients undergoing CAR T-cell therapy. Methods: To address this gap, we conducted a cross-sectional survey on behalf of the Cellular Therapy and Immunobiology Working Party (CTIWP) of the EBMT, distributed from January to April 2025 to centers, assessing current fertility-related practices around CAR T-cell therapy. A second, complementary questionnaire was then circulated to gather detailed information on reported pregnancies following CAR T treatment. Results: In total, 99 centers out of 247 (40%) answered and were included in the analysis. A total of 23 pregnancies were reported in 18 patients, resulting in 18 live births, 1 ongoing pregnancy, and 4 miscarriages at the time of data censoring. Seventeen pregnancies occurred in female CAR T-cell recipients, and six were reported by male recipients through their partners. In patient achieving pregnancy, B cell lymphoma was the most common indication for treatment. Notably, pregnancies in the female cohort occurred naturally in 82% of cases (14/17). Among the patients with available information, the median time between CAR T-cell infusion and delivery or miscarriage was 3 years, (range 4 months to 6 years). Although both low- and high-grade Cytokine Release Syndrome (CRS) and Immune Effector Cell–Associated Neurotoxicity Syndrome (ICANS) were reported among these patients, these events did not appear to influence pregnancy outcomes, acknowledging the small sample size. Moreover, with the questionnaire we assessed the different procedures regarding fertility across centers. While most centers reported offering fertility counselling before CAR T-cell infusion, 11 centers (17%) indicated that they do not routinely inform patients of the potential reproductive risks; indeed, most centers (79%) offered fertility preservation procedures to male and female patients. Additionally, 41 % of the reporting centers do not routinely provide psychological support during CAR T-cell therapy. The most common barriers to fertility preservation referral were the urgency of initiating bridging therapy to CAR T-cell infusions due to active or rapidly progressive disease in aggressive disease and extensive prior chemotherapy exposure, defined as more than three previous treatment lines. Among male patients, semen collection and cryopreservation were the most frequently used methods (93%). For female patients, the predominant approaches were oocyte cryopreservation (63%) and ovarian tissue cryopreservation (59%). Endocrinologic follow-up practices after CAR T-cell therapy varied substantially across centers. Conclusions: We report the largest series of pregnancies and live births after–CAR T. As CAR T-cell therapy is increasingly administered earlier in the treatment algorithms and to younger populations, integrating standardized fertility counselling and preservation strategies into routine care will be essential. The reproductive success highlights the urgent need for robust research and formalized guidelines in this evolving field.
- 2 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (805) , eado9511
A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice
Chimeric antigen receptor (CAR) T cells have shown limited efficacy against solid tumors because of poor tissue penetration, constrained activity, and early exhaustion due to the immunosuppressive tumor microenvironment (TME). Although stimulatory cytokines can counteract immune suppression, their systemic administration entails risk of toxicities and counter-regulatory responses. Here, we leveraged a population of tumor-associated TIE2-expressing macrophages (TEMs) to release interferon-α (IFN-α) and/or orthogonal interleukin-2 (oIL2) at the tumor site. Targeted cytokine delivery rescued CAR T cell functionality against the clinically relevant tumor antigen B7-homolog 3 (B7-H3) in an orthotopic, CAR T cell–refractory, immunocompetent mouse model of glioblastoma (GBM) named mGB2 that recapitulates pathological features of the human disease. Immunophenotypic and transcriptomic analyses revealed that inhibition of premature terminal exhaustion and induction of effector and memory states featuring activation of signaling pathways and transcriptional networks putatively boosted CAR T cell antitumor activity. Furthermore, IFN-α, especially when combined with private oIL2 signaling to CAR T cells, elicited potent endogenous T cell responses against multiple tumor-associated antigens, leading to delayed GBM growth and prolonged mouse survival even with tumors expressing B7-H3 in only a fraction of cells. These data suggest that the combination of TEM-based cytokine delivery and CAR T cells may have synergistic effects and support the further study of this approach for the treatment of patients with GBM.
- 2 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (805) , eado9511
A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice
Chimeric antigen receptor (CAR) T cells have shown limited efficacy against solid tumors because of poor tissue penetration, constrained activity, and early exhaustion due to the immunosuppressive tumor microenvironment (TME). Although stimulatory cytokines can counteract immune suppression, their systemic administration entails risk of toxicities and counter-regulatory responses. Here, we leveraged a population of tumor-associated TIE2-expressing macrophages (TEMs) to release interferon-α (IFN-α) and/or orthogonal interleukin-2 (oIL2) at the tumor site. Targeted cytokine delivery rescued CAR T cell functionality against the clinically relevant tumor antigen B7-homolog 3 (B7-H3) in an orthotopic, CAR T cell–refractory, immunocompetent mouse model of glioblastoma (GBM) named mGB2 that recapitulates pathological features of the human disease. Immunophenotypic and transcriptomic analyses revealed that inhibition of premature terminal exhaustion and induction of effector and memory states featuring activation of signaling pathways and transcriptional networks putatively boosted CAR T cell antitumor activity. Furthermore, IFN-α, especially when combined with private oIL2 signaling to CAR T cells, elicited potent endogenous T cell responses against multiple tumor-associated antigens, leading to delayed GBM growth and prolonged mouse survival even with tumors expressing B7-H3 in only a fraction of cells. These data suggest that the combination of TEM-based cytokine delivery and CAR T cells may have synergistic effects and support the further study of this approach for the treatment of patients with GBM.
- 11 March 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
In the Right Place and the Right State: Spatial Crosstalk and Immune State Dictate Leukemia Response to Immunotherapy
Donor Lymphocyte Infusion (DLI) is a crucial therapeutic strategy for relapsed myeloid malignancies post-allogeneic hematopoietic cell transplantation (allo-HCT), leveraging the graft-versus-leukemia (GvL) effect to restore immune control. While highly effective in chronic myeloid leukemia (CML), its efficacy in acute myeloid leukemia (AML) remains limited, with underlying mechanisms not fully understood. Recent research by Maurer and colleagues utilized cutting-edge technologies to dissect immune-leukemia interactions within the bone marrow niche, identifying a cytotoxic CD8+ T cell population as a key mediator of the anti-leukemic response. The study highlights a dynamic expansion of T and NK cells in responders, whereas non-responders display an immune suppressive bone marrow niche. TCR tracking revealed that the primary effectors of GvL in AML originate from the DLI infusion, yet their activation depends on a permissive bone marrow microenvironment. These insights emphasize that leukemia progression and immune response are shaped not only by malignant cells but also by broader niche dynamics. Further investigation is needed to define the different mechanisms that drives response or resistance to cellular therapies, but also to dissect the antigenic specificity of GvL-mediating T cells and define biomarkers predicting response to DLI.
- 11 March 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
In the Right Place and the Right State: Spatial Crosstalk and Immune State Dictate Leukemia Response to Immunotherapy
Donor Lymphocyte Infusion (DLI) is a crucial therapeutic strategy for relapsed myeloid malignancies post-allogeneic hematopoietic cell transplantation (allo-HCT), leveraging the graft-versus-leukemia (GvL) effect to restore immune control. While highly effective in chronic myeloid leukemia (CML), its efficacy in acute myeloid leukemia (AML) remains limited, with underlying mechanisms not fully understood. Recent research by Maurer and colleagues utilized cutting-edge technologies to dissect immune-leukemia interactions within the bone marrow niche, identifying a cytotoxic CD8+ T cell population as a key mediator of the anti-leukemic response. The study highlights a dynamic expansion of T and NK cells in responders, whereas non-responders display an immune suppressive bone marrow niche. TCR tracking revealed that the primary effectors of GvL in AML originate from the DLI infusion, yet their activation depends on a permissive bone marrow microenvironment. These insights emphasize that leukemia progression and immune response are shaped not only by malignant cells but also by broader niche dynamics. Further investigation is needed to define the different mechanisms that drives response or resistance to cellular therapies, but also to dissect the antigenic specificity of GvL-mediating T cells and define biomarkers predicting response to DLI.
- 23 July 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (10) , 1486-1490
Challenges and successes in cellular therapies and CAR-T: insights from the 50th EBMT annual meeting
- 23 July 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (10) , 1486-1490
Challenges and successes in cellular therapies and CAR-T: insights from the 50th EBMT annual meeting